Conv. Plasma
Nigella Sativa

All quercetin studies
Meta analysis
study COVID-19 treatment researchQuercetinQuercetin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 86% Improvement Relative Risk ICU admission 40% Time to discharge from e.. 32% Quercetin  Shohan et al.  LATE TREATMENT  RCT Is late treatment with quercetin beneficial for COVID-19? RCT 60 patients in Iran (December 2020 - January 2021) Faster recovery with quercetin (p=0.039) Shohan et al., European J. Pharmacology, Dec 2021 Favors quercetin Favors control

The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial

Shohan et al., European Journal of Pharmacology, doi:10.1016/j.ejphar.2021.1746158
Dec 2021  
  Source   PDF   All   Meta
Quercetin for COVID-19
24th treatment shown to reduce risk in July 2021
*, now known with p = 0.0031 from 11 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
Small RCT with 60 severe hospitalized patients in Iran, 30 treated with quercetin, showing shorter time until discharge. All patients received remdesivir or favipiravir, and vitamin C, vitamin D, famotidine, zinc, dexamethasone, and magnesium (depending on serum levels). Quercetin 1000mg daily for 7 days. IRCT20200419047128N2.
This is the 5th of 10 COVID-19 RCTs for quercetin, which collectively show efficacy with p=0.0049.
This is the 6th of 11 COVID-19 controlled studies for quercetin, which collectively show efficacy with p=0.0031.
risk of death, 85.7% lower, RR 0.14, p = 0.24, treatment 0 of 30 (0.0%), control 3 of 30 (10.0%), NNT 10.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of ICU admission, 40.0% lower, RR 0.60, p = 0.71, treatment 3 of 30 (10.0%), control 5 of 30 (16.7%), NNT 15.
time to discharge from end of intervention, 32.4% lower, relative time 0.68, p = 0.04, treatment 30, control 30.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shohan et al., 2 Dec 2021, Randomized Controlled Trial, Iran, peer-reviewed, mean age 50.9 (treatment) 52.7 (control), 8 authors, study period December 2020 - January 2021, average treatment delay 7.8 days. Contact:,
This PaperQuercetinAll
The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial
Mojtaba Shohan, Roohangiz Nashibi, Mohammad-Reza Mahmoudian-Sani, Farhad Abolnezhadian, Seyed Mehri Ghafourian, Seyed Mohammad Alavi, Asaad Sharhani, Dr Ali Khodadadi
European Journal of Pharmacology, doi:10.1016/j.ejphar.2021.174615
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Authorship contribution statement Mojtaba Shohan: Conceptualization, Methodology, Writing original draft, Writingreview and editing. Roohangiz Declarations of interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Agrawal, Agrawal, Blunden, Quercetin: Antiviral Significance and Possible COVID -19 Integrative Considerations, Natural Product Communications
Ahmed, Abdelseed, Albalawi, Almutairi, Alsalameen et al., Evaluation of the Effect of Zinc, Quercetin, Bromelain and Vitamin C on COVID-19 Patients
Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the treatment of Covid-19, New England Journal of Medicine
Biancatelli, Berrill, Catravas, Marik, Dabbous et al., Quercetin and vitamin C: an experimental, synergistic therapy for the prevention and treatment of SARS-CoV-2 related disease (COVID-19), Frontiers in immunology
Carpinteiro, Edwards, Hoffmann, Kochs, Gripp et al., Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS -CoV-2 by epithelial cells, Cell Reports Medicine
Carpinteiro, Gripp, Hoffmann, Pöhlmann, Hoertel et al., Inhibition of acid sphingomyelinase by ambroxol prevents SARS -CoV-2 entry into epithelial cells, Journal of Biological Chemistry
Chamorro, Pandolfi, Moreno, Barreira, Martínez-Ramas et al., Effects of quercetin in a rat model of hemorrhagic traumatic shock and reperfusion, Molecules
Dabbous, El-Sayed, El Assal, Elghazaly, Ebeid et al., Safety and efficacy of favipiravir versus hydroxychloroquine in man agement of COVID-19: A randomised controlled trial, Scientific reports
Derosa, Maffioli, D'angelo, Di Pierro, A role for quercetin in coronavirus disease 2019 (COVID-19), Phytotherapy Research
Di Pierro, Derosa, Maffioli, Bertuccioli, Togni et al., Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early -Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study
Glinsky, Tripartite combination of candidate pandemic mitigation agents: vitamin D, quercetin, and estradiol manifest properties of medicinal agents for targeted mitigation of the COVID-19 pandemic defined by genomics-guided tracing of SARS-CoV-2 targets in human cells, Biomedicines
Grein, Ohmagari, Shin, Diaz, Asperges et al., Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study, New England Journal of Medicine
Hoertel, Sánchez-Rico, Gulbins, Kornhuber, Carpinteiro et al., Association between FIASMAs and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID-19: an observational multicenter study, Clinical Pharmacology & Thera peutics
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patien ts infected with 2019 novel coronavirus in Wuhan, China, The lancet
Jo, Kim, Shin, Kim, Inhibition of SARS-CoV 3CL protease by flavonoids, Journal of enzyme inhibition and medicinal chemistry
Kaka, Macdonald, Greer, Vela, Duan-Porter et al., Major update: remdesivir for adults with COVID-19: a living systematic review and meta -analysis for the American College of Physicians Practice Points, Annals of internal medicine
Lenze, Mattar, Zorumski, Stevens, Schweiger et al., Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID -19: a randomized clinical trial, Jama
Li, Yao, Han, Yang, Chaudhry et al., Metabolic Signatures Associated with Severity in Hospitalized COVID-19 Patients
Moon, Barritt, Mortaz, Tabarsi, Varahram et al., Elevated Liver Enzymes in Patients with COVID-19: Look, but Not Too Hard, Frontiers in Immunology
Murohashi, Hagiwara, Kitayama, Yamaya, Higa et al., Outcome of early-stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: A report of 11 cases, Respiratory investigation
Nile, Nile, Qiu, Li, Jia et al., COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons, Cytokine & growth factor reviews
Onal, Arslan, Ergun, Topuz, Semerci et al., Treatment of COVID-19 Patients with Quercetin: A Prospective, Single-Centre, Randomized, Controlled Trial
Ros, Pedrera, Garcia-Saez, Saeedi-Boroujeni, Mahmoudian-Sani, Partners in crime: the interplay of proteins and membranes in regulated necrosis, International journal of molecular sciences
Seftel, Boulware, Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19
Shinkai, Tsushima, Tanaka, Hagiwara, Tarumoto et al., Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial, Infectious Diseases and Therapy
Singh, Khera, Chugh, Khera, Chugh, Efficacy and safety of remdesivir in COVID -19 caused by SARS-CoV-2: a systematic review and meta-analysis, BMJ open
Ucan, Cerci, Efe, Akgun, Ozmen et al., Benefits of treatment with favipiravir in hospitalized patients for COVID-19: a retrospective observational case-control study, Frontiers in immunology
Zhao, Di, Xu, The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies, Cytokine & Growth Factor Reviews
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop